June 29 (Reuters) – BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to build its rare-disease pipeline and streamline expenses.
Shares of the drugmaker were down nearly 2% in premarket trading.
• The company said it will leverage partnerships and its own commercial infrastructure to focus on identifying and advancing high-value rare-disease drug candidates.
• BioCryst lowered its 2026 adjusted operating expense forecast to $420 million to $440 million, compared with its prior view of $450 million to $470 million.
• The company reaffirmed its 2026 revenue forecast for Orladeyo at $625 million to $645 million. Total revenue projection stood at $635 million to $660 million.
• BioCryst markets Orladeyo, an oral treatment approved for hereditary angioedema, a rare disorder that causes recurrent, unpredictable episodes of severe swelling.
• The company said it resolved a manufacturing delay for Orladeyo oral pellets for children aged 2 to under 12 years, and expects the product to be available in early August.
• BioCryst said it will focus on two experimental drugs nearing commercialization: navenibart for HAE and BCX17725 for Netherton syndrome, a rare skin disease.
• The company said top-line data from a late-stage study of navenibart are expected in Q3 2027, while proof-of-concept data for BCX17725 in Netherton syndrome are expected by the end of 2026.
(Reporting by Kunal Das in Bengaluru; Editing by Shreya Biswas)
